Rheumatology
Latest news
98 articles · 20 / page
AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases
AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.
Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w
Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression
The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with n
Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial
The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu
Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia
The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus
Digital Psychological Intervention Reduces Distress and Improves Quality of Life in Inflammatory Rheumatic Diseases: Results from a Pilot RCT
A 102-participant pilot RCT in Germany found that a self-guided digital psychological intervention produced clinically meaningful reductions in psychological distress and modest improvements in quality of life at 3 months in people with inf
Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis
In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesi
Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher pre
EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy: What Clinicians and Researchers Need to Know
EULAR’s first-ever, evidence-based classification criteria for haemochromatosis arthropathy (HA) provide an 8-item, 11-point score (≥5 yields 93.3% specificity, 71.4% sensitivity) to standardize research cohorts of C282Y homozygous patients
EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know
EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care
Long-Term Impact of Treat-to-Target Urate-Lowering Therapy on Ultrasound-Detected Crystal Depositions and Clinical Outcomes: Insights from the 5-Year NOR-Gout Study
The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate co
Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study
In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with pri
UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study
The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA a
Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up
Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to hig
Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective
The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-eff
Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy
The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were simi
Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions
A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi
Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern
A multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is ne
High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS
A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among thos
Browse by specialty
Open language-specific specialty feeds and department pages.